Crossmark

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

Crossref DOI link: https://doi.org/10.1186/s12885-018-4479-2

Published Online: 2018-05-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guida, Michele https://orcid.org/0000-0002-2891-0650
Tommasi, Stefania

Strippoli, Sabino

Natalicchio, Maria Iole

De Summa, Simona

Pinto, Rosamaria

Cramarossa, Antonio

Albano, Anna

Pisconti, Salvatore

Aieta, Michele

Ridolfi, Ruggiero

Azzariti, Amalia

Guida, Gabriella

Lorusso, Vito

Colucci, Giusepe
License Information

Text and Data Mining valid from 2018-05-10
More Information

Article History

Received: 8 July 2016

Accepted: 2 May 2018

First Online: 10 May 2018

Ethics approval and consent to participate

: We declare that this study was approved by the Ethics Committee of National Cancer Research Centre “Giovanni Paolo II”. All patients signed an informed consent.

: The authors declare that they have no conflict of interest. This work was supported by MIUR PON 01_01297 “VIRTUALAB”; and by Onlus Association Maria Ruggieri that is supporting Sabino Strippoli’s grant.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below